Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PR013 in Allergic Conjunctivitis
NCT03368339Phase 2Completed
- Sponsor
- Realm Therapeutics
- Start
- Dec 2017
- Primary completion
- Jan 2018
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PR013 in allergic conjunctivitis (AC), sponsored by Realm Therapeutics. Started Dec 2017; status: completed.
02
Drugs
PR013
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT03368339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03368339.